Compare RMBI & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | GANX |
|---|---|---|
| Founded | 1887 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 112.7M |
| IPO Year | 2019 | 2021 |
| Metric | RMBI | GANX |
|---|---|---|
| Price | $13.25 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 17.4K | ★ 683.2K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | 1.10 | ★ 47.95 |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.80 | $1.41 |
| 52 Week High | $15.24 | $4.34 |
| Indicator | RMBI | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 54.52 |
| Support Level | $13.02 | $2.60 |
| Resistance Level | $14.31 | $2.79 |
| Average True Range (ATR) | 0.37 | 0.22 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 15.33 | 36.88 |
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.